

Date: 20<sup>th</sup> August, 2019

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001

Dear Sir/Madam,

**Sub: Successful US FDA Inspection at Alembic Pharmaceuticals Bioequivalence Facility at Vadodara**

This is to inform the exchange that the Company's Bioequivalence Facility located at Vadodara was inspected by US Food & Drug Administration (USFDA) between 12<sup>th</sup> August, 2019 to 16<sup>th</sup> August, 2019 and between 12<sup>th</sup> August, 2019 to 20<sup>th</sup> August, 2019 for

- a) Bioequivalence Bioanalytical; and
- b) Bioequivalence Clinical

There were no 483s issued by USFDA at the end of the inspection.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Alembic Pharmaceuticals Limited**

**Charandeep Singh Saluja**  
Company Secretary

**ALEMBIC PHARMACEUTICALS LIMITED**